Tryngolza Olezarsen Application Scope

Tryngolza (olezarsen) is indicated as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely elevated triglyceride levels due to impaired function of the enzyme lipoprotein lipase (LPL) .

Tryngolza Olezarsen Characteristics

Ingredients Active Ingredient: Olezarsen sodium (an apolipoprotein C-III-directed antisense oligonucleotide). Excipients: Specific excipients are detailed in the full prescribing information.
Properties: Olezarsen binds to apolipoprotein C-III mRNA, leading to its degradation. This action increases the clearance of plasma triglycerides and very low-density lipoprotein (VLDL), thereby reducing triglyceride levels .
Packaging Specification: Available as an 80 mg/0.8 mL solution in a single-dose autoinjector .
Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
After removal from refrigeration, the autoinjector can be stored at room temperature (15°C to 30°C [59°F to 86°F]) for up to 6 weeks. Discard if not used within this period.
Do not freeze or expose to heat.
Expiry Date: Refer to the expiration date printed on the packaging.
Executive Standard: Complies with FDA regulations and standards for approved medications.
Approval Number: FDA Approval Date: December 19, 2024 .
Date of Revision: December 2024 .
Manufacturer: Ionis Pharmaceuticals, Inc.

Guidelines for the Use of Tryngolza Olezarsen

Dosage and Administration:

Recommended dose: 80 mg administered subcutaneously once monthly.
Injection sites: Abdomen or front of the thigh. The back of the upper arm can be used if administered by a healthcare provider or caregiver.
Patients should be instructed on proper preparation and administration techniques .

Adverse Reactions:
Common adverse reactions (incidence >5% and >3% higher than placebo) include:

Injection site reactions (19%)
Decreased platelet count (12%)
Arthralgia (9%) .

Contraindications:

History of serious hypersensitivity reactions to olezarsen or any of its excipients .

Precautions:

Monitor for signs of hypersensitivity reactions, including bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias. Discontinue use if such reactions occur .
Safety and efficacy have not been established in patients under 18 years of age .

Interactions

Drug Interactions:
No significant drug interactions have been identified. However, patients should inform their healthcare provider of all medications they are taking to assess potential interactions.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.